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Abstract
Background AF-16 is a 16-amino-acid-long peptide derived
from the amino-terminal part of the endogenous protein,
antisecretory factor (AF). AF-16 in vivo has been shown to
regulate dysfunctions in the water and ion transport system
under various pathological conditions and also to counteract
experimentally increased tissue pressure.
Methods Rats were subjected to a cryogenic brain injury in
order to increase the intracranial pressure (ICP). The distribu-
tion of AF-16 in blood and CSF after intravenous or intranasal
administration was determined in injured and control rats. ICP
was monitored in freely moving, awake rats, by means of an
epidural pressure transducer catheter connected to a wireless
device placed subcutaneously on the skull. The continuous
ICP registrations were achieved by means of telemetry.
Results Intranasal administration of AF-16 resulted in a sig-
nificantly higher CSF concentrations of AF-16 in injured than
in control rats, 1.3 versus 0.6 ng/ml, whereas no difference
between injured and control rats was seen when AF-16 was
given intravenously. Rats subjected to cryogenic brain injury
developed gradually increasing ICP levels. Intranasal admin-
istration of AF-16 suppressed the increased ICP to normal
values within 30 min.
Conclusion Optimal AF-16 concentrations in CSF are
achieved after intranasal administration in rats subjected to a
cryogenic brain injury. The ability of AF-16 to suppress an
increased ICP was manifested.
Keywords AF-16 uptake . Intranasal administration . Brain
oedema . Intracranial pressure . Telemetry . Continuous
recording . Rat
Introduction
A pathological rise in intracranial pressure (ICP) may occur as
a response to major stroke and trauma. Patients affected by
these conditions are most often subjected to an increased acute
mortality and long-term morbidity with significant neurolog-
ical deficits [1–3]. AF-16, a 16-amino-acid-long peptide de-
rived from the amino-terminal part of the endogenous protein,
antisecretory factor (AF), [4, 5] reduces high ICP in rats with
experimentally induced herpes type 1 virus encephalitis [6].
Preliminary observations indicate that AF-16 also suppresses
high ICP resulting from focal cryogenic brain injury [7].
Further investigation of AF-16 as a putative regulator of ICP
is therefore merited.
Previous studies have demonstrated suppressive effects of
AF-16 on increased tissue pressure in tumours [8]. The mod-
ulating influence of AF-16 under these conditions is achieved
after intravenous (i.v.) or intranasal administration.
Measurements of the therapeutic concentrations of AF-16
have, however, not been made. In the present study the AF-
16 concentrations in plasma and cerebrospinal fluid (CSF)
were determined after intranasal and after i.v. administration
of the peptide in control rats and in rats subjected to a focal
cryogenic brain injury.
In a separate set of experiments, the effects of AF-16 on
ICP were recorded. A number of methods for measuring ICP
in anaesthetised rats have been described, including epidural
monitors, subdural, ventricular and cisterna magna catheters,
intra-parenchymal transducers and, recently, lumbar cannula-
tion (for a comprehensive overview see Uldall et al. [9]).
These techniques provide relevant data, but during the
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registrations the central nervous system (CNS) tissue is ex-
posed to anaesthetic drugs which might affect ICP recordings.
In addition, registration of ICP mainly with intra-parenchymal
and intra-ventricular probes usually gives higher and more
fluctuating values than probes placed epidurally, and leads to
an increased risk of intra-parenchymal haematoma and hydro-
cephalus [9].
Silasi et al. [10] were the first to use telemetry blood
pressure transmitters to monitor the ICP in awake rats. The
technique they used, based on a method developed by Data
Science International (DSI), was complicated. In the present
study, we present a modified method for continuous, long-
term measurement of ICP by the DSI technique in order to
allow recording of AF-16 effects in un-anaesthetised and
freely moving rats. Recordings were made through a
pressure-sensitive transducer catheter inserted epidurally and
connected to a small device which is radiometrically connect-
ed to a computer system.
In summary, the results show that the concentration of AF-
16 in plasma is about ten-times higher than in CSF after both
i.v. and intranasal administration of the peptide. Intranasal
administration gave a significantly higher CSF concentration
of AF-16 in animals subjected to a cryogenic brain injury
compared with uninjured controls. Furthermore, AF-16 ad-
ministered intranasally suppressed increased ICP in the in-
jured animals in a significant manner.
Materials and methods
Animals
The test protocol was approved by the Regional Animal
Experiments Ethical Committee and performed in accordance
with guidelines for animal experiments (EC Directive 86/609/
EEC). Male Sprague–Dawley rats, 180±20 g body weight
(Nova-SCB, Sollentuna, Sweden) were used. The rats were
allowed a week for general adaptation in their cages before
any form of experimental procedure was performed. All rats
had free access to water and pelleted food during the whole
experimental period. The temperature and air ventilation in the
animal quarters were monitored according to standard
procedures.
Chemicals
AF-16, produced by organic solid phase synthesis, was pur-
chased from Ross-Pedersen (K.J. Ross-Pedersen ApS,
Klampenborg, Denmark). The peptide was purified by
reversed-phase chromatography and analysed by amino acid
analysis and mass spectrometry. The purity of AF-16 was
about 97 %. The AF-16 peptide, VCHSKTRSNPENNVGL,
was labelled with 14C in the N-terminal valine, specific
activity 50 mC/mmol, 2 μM/ml (American Radiolabeled
Chemicals, Saint Louis, Mo, USA). Marcaine® was pur-
chased from AstraZeneca (Södertälje, Sweden), Isoflurane®
from Baxter Medical (Kista, Sweden).
Surgical procedure for cryogenic brain injury
The operation procedure started with general anaesthesia via
inhalation of Isoflurane (4 % induction, 1.5–2 % maintenance
in air), after which the anaesthetised rat was positioned on the
abdomen on a heating pad. The body temperature was mon-
itored via a rectal thermo-coupled probe, and a heated blanket
was placed underneath the rat in order to keep the temperature
at 37 °C. The head was shaved and the skin washed with 70%
alcohol, followed by a subcutaneous injection of Marcaine. A
3– to 4-cm-long midline incision was made through the skin
and fascia on the skull vault. The skull bone was freed from
adherent connective tissue and a copper rod (144 g) with a tip
diameter of 4 mm was immersed in liquid nitrogen and then
applied to the right parietal bone for 90 s. This freezing
procedure penetrated the bone and induced a defined morpho-
logical injury in the underlying brain tissue The midline of the
cranium was avoided in order not to induce any damage to the
superior sagittal sinus. The resulting lesion volume was cal-
culated after termination of the experiments (see below).
Uninjured rats were used as controls.
Preparation for continuous ICP recordings
The pressure transducer catheter (PA-C10, Data Sciences
International, St. Paul, MN, USA) was inserted into a plastic
cannula. The plastic cannula was 3 mm long with an inner
diameter of 0.40 mm and an outer diameter of 0.80 mm
(Intramedic Polyethylene Tubing, BD, Franklin Lake, NJ,
USA). The pressure devices were calibrated before shipping.
Before implantation the calibration of each probe was verified
according to the instructions given by the DSI manual. The
individual components of the system for ICP recording are
shown in Fig. 1.
Implantation of ICP recording probe
After imposing the cryogenic brain injury on the right hemi-
sphere, a hole (diameter 1 mm) was drilled on the right side of
the parietal bone 3–4 mm lateral to the midline and 2 mm
posterior from the skull bregma mark, followed by free-
dissecting the dura from the bone 3–5 mm anteriorly to the
hole. The tip of the sensor probe, which was connected
directly to the wireless transducer, was inserted anteriorly into
the epidural space with the cannula covering the burr hole.
Prior to implantation, the offset reading of each probe was
recorded, and this value was subtracted from the ICP record-
ings throughout the experiment. Dental cement was applied
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around the cannula in the burr hole in order to fixate the probe
to the bone and avoid air leakage into the epidural space. The
transducer device was placed under the head skin, which was
then closed by ethilone sutures. After completion of surgery,
the rat recovered in its cage, which was placed on top of a
receiver (Model RPC-1; Data Sciences International, New
Brighton, UK) connected to a computer equipped with
dataquest A.R.T. 2.2 software (Data Sciences International,
New Brighton, UK). ICP could then be continuously moni-
tored in the awake and drug-free rat for the rest of the exper-
imental period. A freely moving rat with an implanted device
is shown in Fig. 2.
Intranasal administration of AF-16
Rats were anaesthetised with Isoflurane 24 h after the
cryogenic brain injury. The rats were given a single dose
of 25 μl of AF-16 (2,000 μg/ml in phosphate buffered
saline, PBS) or 14C-AF-16 in each nostril and were then
placed on their backs to make sure the AF-16 solution was
absorbed appropriately. After 5–8 min they had recovered
from anaesthesia, were fully awake and moved freely in the
cage. Control, injured rats received the same volume of
vehicle (PBS) only. ICP recordings for statistical calcula-
tions were collected for a 20-min-long period, starting after
the animals were fully awake and the ICP values were
stable and back to pre-anaesthesia levels.
Calculation of lesion volume and histology
At the end of the experiments the rats were again
anaesthetised, the thorax opened, vena cava inferior cut
open and the rats were terminated by bleeding. The skull
was opened, and the brain carefully dissected out and
placed into 4 % buffered formaldehyde for about 1 week.
The lesion volume resulting from the cryogenic injury was
estimated by measuring the radius of the damaged area on
the surface of the fixated brain with the aid of a calliper and
using the formula: 2 V = 4/3×π×r3. We assumed that the
injured area represented half a sphere. In order to visualise
the histology of the lesion, five brains were embedded in
paraffin, sectioned and stained with cresyl violet, using
standard procedures.
Blood and CSF sampling
The collection of blood and CSF was done in a separate set
of experiments. 14C-Labelled or unlabelled AF-16 was
given by intranasal (see above) or i.v. administration via
the penis vein (25 μl in a volume of 0.5 ml). For measure-
ment of blood concentration of AF-16 the heart was punc-
tured from the right thoracic cavity with an O.D. 1.22/
60 mm injection needle. When 10–12 ml of blood had
been collected, the thorax was opened and the rats were
terminated by removing the heart. Immediately after ter-
mination, the rats were placed on the abdomen. For mea-
surement of CSF levels of AF-16 the dura over cisterna
magna was micro-surgically exposed by dissecting the
neck muscles laterally, a procedure which uncovers the
midline. The dura was subsequently punctured by a
Neoflon i.v. cannula, outer diameter 0.6 mm, length
19 mm. After removing the needle from the cannula, 50–
100 μl of CSF could be aspired without being contaminat-
ed with blood.
Analyses of AF-16 in plasma and CSF
A Bachem AF-16 Enzyme Immunoassay kit (item
S-1403) was used. Heparin-treated blood samples were
mixed with an equal volume of Alsevers citrate solution
(glucose, 0.1 M, sodium citrate 2-hydrate, 0.03 M, sodium
chloride, 0.07 M). The blood samples were stored frozen
for up to 1 month at −20 °C. The laboratory procedure
followed Protocol III in the Bachem kit manual, but some
critical points should be emphasised. The standard AF-16
Fig. 1 The various parts of the device for ICP recording: pressure
transducer (1), transducer catheter (2), plastic cannula (3) and tip of the
sensor probe (4)
Fig. 2 Freely moving rat with the measuring device on the skull
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was dissolved and diluted in normal blood plasma; the
standards S1-S6 (0.2–200 ng/ml, corresponding to 0.114–
114 nM) and normal plasma S0 were distributed into
smaller aliquots (e.g. 200 μl) and frozen at −20 °C until
use. The standard is not stable in buffered saline at these
concentrations. After dissolving the biotinylated tracer in
enzyme immunological assay buffer, the solution was
used within a week or was alternatively frozen in smaller
aliquots until use. After adding samples and antiserum to
the wells, mixing was achieved with a pipette. After
addition of 2 M HCl, mixing was avoided and the absor-
bance was read at 450 nm. The AF-16 levels in CSF were
under the detection level of the AF-16 Enzyme
Immunoassay. It was therefore estimated from the radio-
activity achieved after injection of 14C-AF-16. The
immunochemical and the radioactive method gave similar
values in blood and in CSF
Autoradiography
The distribution of 14C-AF-16 in the brain after intranasal
administration was investigated in a separate set of exper-
iments. Control, uninjured rats (n=10) received one intra-
nasal dose of 14C-AF-16. Thirty minutes later the rats
were terminated and the brains were dissected out as
described above. Frontal slices were cut, about 3 mm
thick, immersed in 10 % sucrose in PBS overnight and
then frozen in liquid nitrogen. Cryosections, cut at 10 μm,
were prepared, air dried and exposed to Biomax AR
autoradiography film (Kodak).
Fig. 3 a AF-16 was deposited
intranasally (0.3 μmol/kg in
25 μl) under Isoflurane
anaesthesia, after which the
concentration (ng/ml) of the
peptide was determined in plasma
(filled bars) and in CSF (unfilled
bars) after a 15-min- or a 30-min-
long period. Higher levels of AF-
16 are found in plasma than in
CSF at both times. Mean ± SEM.
b Autoradiography showing
distribution of 14C-AF-16 in the
rat brain 30 min after intranasal
administration of the peptide. X-
ray film showing signal in the
lateral (LV) and third ventricles
(3V); hc hippocampus
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Statistics
Statistical analyses were performed using one-way Student’s
t-test, and a value of p<0.05 was regarded as statistically
significant.
Results
AF-16 in blood and in CSF
Blood and CSF samples were collected 15 and 30 min after the
intranasal deposition of AF-16 in normal animals and peptide
concentrations were determined by enzyme-linked immunosor-
bent assay (ELISA) (Fig. 3a). The concentration of AF-16 was
about ten-times higher in plasma than in CSF at both sampling
points. The plasma levels decreased significantly between 15
and 30 min (p<0.03), which indicates a rapid turnover rate of
plasma AF-16. The decrease of AF-16 in CSF was not statis-
tically significant. Autoradiography showed that 14C-AF-16
could be detected in the brain ventricles/choroid plexus
30 min after intranasal administration (Fig. 3b).
To compare the two different administration routes, blood
and CSF samples were collected 30 min after an intranasal or
an i.v. deposition of AF-16. The samples were collected both
from uninjured control animals and from experimental ani-
mals subjected to cryogenic injury. In all animals the
concentration of AF-16 was about ten-times higher in plasma
than in CSF (Table 1). The AF-16 concentration in CSF was
similar in control rats and in experimental rats after i.v. ad-
ministration. Using the intranasal route, however, AF-16 ad-
ministration resulted in a significantly higher CSF concentra-
tion in experimental than in control rats (p=0.01; Table 1).
Thus, compared with the i.v. route, the intranasal route gave a
similar or higher concentration of AF-16 in the CSF. The
intranasal route was therefore chosen for the following ICP
experiments. This route is also a less invasive way of giving
the peptide to the rats.
ICP measurements
The ICP measured epidurally in normal, uninjured rats was
3.15±1.4 mmHg (n=10). The ICP varied with heart beat and
respiration (Fig. 4). The cryogenic injury did not induce any
form of neurological deficits or abnormal movement patterns
in the rats. The animals were moving and feeding normally.
ICP measurements collected after the cryogenic injury
showed that the ICP started to increase 2–3 h after the injury,
peaking between 12 and 24 h.
Effect of treatment with AF-16 or PBS vehicle
The induction of anaesthesia caused a transient increase in ICP
(Fig. 5), but after 3–5 min ICP returned to pre-treatment levels,
Table 1 Concentrations of AF-
16 in plasma and in CSF after
intravenous and intranasal ad-
ministration in control and exper-
imental rats
Control rats subjected to no form
of treatment, Experimental rats
subjected to acryogenic brain in-
jury; i.v. intravenous administra-
tion, i.n. intranasal administra-
tion; NS not significant
Group Administration
route
Fluid n Mean ± SEM
(ng/ml)
p
Control i.v. Plasma 7 14.7±0.6 NS
Experimental i.v. Plasma 7 14.5±0.9
Control i.v. CSF 6 1.1±0 NS
Experimental i.v. CSF 7 1.1±0.1
Control i.n. Plasma 9 7.8±0.7 NS
Experimental i.n. Plasma 9 8.7±0.5
Control i.n. CSF 9 0.6±0.1 0.01
Experimental i.n. CSF 9 1.3±0.2
Fig. 4 ICP recording from a
control rat showing pulsations
due to the heart beats
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Fig. 5 Recordings of ICP 24 h after a cryogenic injury. aBefore anaesthesia. b Transient increase in ICP during induction of anaesthesia. cReturn to the
pre-anaesthetic level after a couple of minutes. d Reduced ICP 30 min after AF-16 administration
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after which AF-16 or the vehicle (PBS) was administered
intranasally. Table 2 shows themean decrease in ICP in percent
after intranasal administration of AF-16 or PBS, respectively.
The decrease in ICP is calculated as the difference between the
initial, pre-treatment levels and the mean of ICP recordings
during the first 20-min period after the animals had fully
recovered from anaesthesia. ICP decreased from initial, pre-
treatment level of 10.01±1.99 mmHg to 7.93±1.31 mmHg in
rats (n=10) treated intranasally with PBS. In rats (n=10) given
AF-16 intranasally the ICP decreased from 10.06±1.84mmHg
to 6.09±1.03 mmHg. The ICP reduction was significantly
larger in the AF-16-treated animals than in the PBS-treated
animals (p<0.002). A typical course with reduction in ICP
after intranasal administration of AF-16 in an animal subjected
to a cryogenic brain injury is shown in Fig. 5.
Lesion volume and histology
The mean lesion volume, calculated on the assumption that
the lesion was shaped as a half sphere was 12.2±1.8 mm3 (n=
20). Morphological examination of the cryogenic damage to
the brain showed that the injury appeared as a superficial,
rounded necrosis in the parietal cortex. The histology of a
typical lesion is shown in Fig. 6.
Discussion
In the present study, we further explore the ability of AF-
16 to suppress an elevated ICP utilising an experimental
model of focal brain injury in rats. A significant suppress-
ing effect on the increased ICP was seen after intranasal
administration of AF-16, which reached concentration
levels of about 10 ng/ml in plasma and 1 ng/ml in CSF.
This effect was demonstrated using a modified method for
ICP monitoring where the measuring probe was implanted
epidurally and connected to a wireless device placed sub-
cutaneously on the skull for telemetric recording. This
method allows a continuous registration of ICP in the
freely moving animal not subjected to influences by anaes-
thetic drugs. In our previous studies, ICP was measured
intermittently in anaesthetised animals via a probe inserted
directly into the brain tissue [6, 11, 12,] which in general
gives higher resting ICP values and increases the risk of
mechanical damage and infectious contamination of the
brain tissue [9]. These risks are reduced considerably by
the method for epidural registration used in the present
study. The epidural ICP values in uninjured controls were
in accordance with those reported by others [10] and, based
on these data, we considered values above 6 mmHg as
pathologically raised.
During induction of Isoflurane anaesthesia, a temporary
increase of ICP was registered in controls as well as in
experimental rats. This transient effect on ICP may be attrib-
uted to the prominent relaxation effect of Isoflurane on the
musculature of blood vessels. Thus, this reaction leads to a
vasodilatation with increased blood flow and cerebral perfu-
sion [13, 14]. After autoregulatory compensating mechanisms
become activated due to the increased cerebral perfusion,
blood flow most likely returns to pre-anaesthetic levels, lead-
ing to a decrease in ICP.
In rats given the peptide by the intranasal route, a higher
CSF concentration was obtained in animals subjected to a
focal cryogenic brain injury than in control rats. This was
not seen after i.v. administration. Thus, in injured rats the
intranasal mode of administration appears to be more efficient
than i.v. administration in order to achieve AF-16 penetration
into the CNS. The major part of AF-16 recovered in blood and
in CSF after intranasal administration is probably absorbed
through capillaries and lymphatics in the nasal mucosa. An
additional transport route into CSF after intranasal adminis-
tration is through fluid-filled perineurial channels created by
the olfactory ensheathing cells in the olfactory mucosa [15].
Nasal absorption via these cells has been shown to take from a
few minutes up to 30 min [16, 17], a time span which is
compatible with the results obtained in the present study. In
Table 2 Influence of intranasal administration of AF-16 or PBS on the
increased ICP
Category n Mean ± SEM Significancea
PBS 10 15.9±4.9 p<0.002
AF-16 10 38.1±3.8
Recordings were collected during a 20-min-long period in the awake
animals. The means were used for statistical calculations. The figures
represent ICP decrease in percent (mean ± SEM) in relation to the initial
raised ICP due to a cryogenic brain injury
a Student’s t-test, PBS versus AF-16, two-tailed
Fig. 6 Paraffin section from the brain of an injured rat showing a typical
superficial, rounded lesion. Cresyl violet. Scale bar 500 μm
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addition, it is also possible that a head injury affects this route
by making the epithelium more “leaky”, which might stimu-
late the uptake in CSF. An increased CNS uptake mediated by
an enhanced axoplasmic retrograde transport is less likely,
since it is a slower process which needs hours to days to make
a drug reach the CNS [18].
Several studies have shown differences in uptake and ef-
fects of various drugs depending on administration route [19].
Our previous results demonstrate that i.v. administration of
AF-16 was less effective than intranasal administration in
reducing interstitial fluid pressure in experimentally induced
mammary tumours [8]. This difference might reflect that AF-
16 is more effectively bound to plasma proteins after i.v. than
after intranasal deposition, and that this protein binding in-
hibits the subsequent clinical effects.
AF was originally identified as a potent inhibitor of path-
ological, enterotoxin-induced intestinal fluid secretion [5, 20].
In addition to electrolyte and water transport regulation, AF
acts by counteracting various forms of inflammatory reactions
[21–23]. AF has also been demonstrated to modulate the
proliferation of memory/effector T cells, thereby inhibiting
the severity of experimental autoimmune encephalitis [24,
25], and to inhibit the extent of inflammation in the late phase
of a mouse colitis model [26]. Furthermore, we have shown
that intranasal application of AF-16 suppressed an elevated
ICP and completely abolished the mortality in rats with en-
cephalitis experimentally induced by herpes simplex virus
(HSV-1) [6]. The mechanisms behind the effects of AF-16
on brain tissue are, however, unclear. They may in part be
ascribed to interactions with neuronal cells, since various AF
peptides inhibit GABA and chloride permeation across
Deiters’ neuronal cell membranes in vitro [27]. Bicuculline
abrogates this inhibition, suggesting that AF interacts via the
GABAA receptors [27]. In addition, AF-16 also affects neu-
ronal signalling in the brain. Thus, AF-16 incubation of acute
rat hippocampal slices was followed by a 40 % reduction of
GABAA–mediated synaptic transmission into CA1 pyramidal
cells without affecting glutamatergic transmission [28]. This
inhibitory effect was mimicked by feeding the rats with a diet
containing specially processed cereals or after repeated chol-
era toxin per oral immunisations. Both of these treatments
induce endogenous AF synthesis [28]. No side effects of AF-
16 treatment have been observed during experimental condi-
tions in animals.
In summary, the present study manifests the ability of AF-16
to counteract increased tissue pressure, such as seen under con-
ditions with elevated ICP. New data are supplied on the uptake of
the peptide, showing that intranasal administration is the most
efficient way to achieve a fast delivery of AF-16 to the CNS. The
data also indicate that the turn-over rate of AF-16 is compara-
tively short, suggesting that a continuous administration of the
peptide would probably be optimal for keeping a raised ICP at
normal levels y. The results may serve as a basis for designing
studies in which the modulating ability of AF on ICP can be
further exploited under clinical conditions. In future studies it will
also be of advantage to use micro-dialysis to analyse the extra-
cellular concentration of AF-16.
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